Back

Natriuretic effect of 2 weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function: results of the DAPASALT trial

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Improving Cardiovascular Function and Clinical Outcome in Diabetes Using New Guideline-Based Pharmacotherapy Antidiabetic Pharmacotherapy ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Hiddo Heerspink

University Medical Centre Groningen, Groningen (Netherlands (The))

7 More presentations in this session

Presentation thumbnail
Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial.
Doctor G. Ferrannini (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR and albuminuria: a REWIND post hoc subgroup analysis
Professor H. Colhoun (Edinburgh, GB)
Abstract Slides Video
Presentation thumbnail
Direct effects of canagliflozin on human myocardial redox signalling: a novel role for SGLT1 inhibition
Doctor H. Kondo (Yufu City, JP)
Abstract Slides Video
Presentation thumbnail
Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME
Professor S. Verma (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
The effects of empagliflozin on arterial stiffness, endothelial function and ventriculoarterial coupling in type 2 diabetes mellitus: 1 year follow up
Doctor I. Ikonomidis (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Improving Cardiovascular Function and Clinical Outcome in Diabetes Using New Guideline-Based Pharmacotherapy

The Event

Event poster

ESC Congress 2020

29 August - 1 September 2020
You may be interested in
thumbnail
Congress Presentation
Case 1 - a middle-aged male with T2DM: polypharmacy in a primary prevention setting
thumbnail
Congress Presentation
Hypertension and glucose
thumbnail
Congress Presentation
Cardiovascular risk reduction: should we target pre-diabetes?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources